The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuse...

Descripción completa

Detalles Bibliográficos
Autores principales: Goker Bagca, Bakiye, Biray Avci, Cigir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305753/
https://www.ncbi.nlm.nih.gov/pubmed/32636055
http://dx.doi.org/10.1016/j.cytogfr.2020.06.013
_version_ 1783548530684592128
author Goker Bagca, Bakiye
Biray Avci, Cigir
author_facet Goker Bagca, Bakiye
Biray Avci, Cigir
author_sort Goker Bagca, Bakiye
collection PubMed
description Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potential effectiveness of ruxolitinib is suggested by evaluating the interactions of these potential targets with ruxolitinib or JAK/STAT pathway.
format Online
Article
Text
id pubmed-7305753
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-73057532020-06-22 The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19 Goker Bagca, Bakiye Biray Avci, Cigir Cytokine Growth Factor Rev Article Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potential effectiveness of ruxolitinib is suggested by evaluating the interactions of these potential targets with ruxolitinib or JAK/STAT pathway. Elsevier Ltd. 2020-08 2020-06-20 /pmc/articles/PMC7305753/ /pubmed/32636055 http://dx.doi.org/10.1016/j.cytogfr.2020.06.013 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Goker Bagca, Bakiye
Biray Avci, Cigir
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
title The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
title_full The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
title_fullStr The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
title_full_unstemmed The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
title_short The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
title_sort potential of jak/stat pathway inhibition by ruxolitinib in the treatment of covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305753/
https://www.ncbi.nlm.nih.gov/pubmed/32636055
http://dx.doi.org/10.1016/j.cytogfr.2020.06.013
work_keys_str_mv AT gokerbagcabakiye thepotentialofjakstatpathwayinhibitionbyruxolitinibinthetreatmentofcovid19
AT birayavcicigir thepotentialofjakstatpathwayinhibitionbyruxolitinibinthetreatmentofcovid19
AT gokerbagcabakiye potentialofjakstatpathwayinhibitionbyruxolitinibinthetreatmentofcovid19
AT birayavcicigir potentialofjakstatpathwayinhibitionbyruxolitinibinthetreatmentofcovid19

Ejemplares similares